RGNX
REGENXBIO Inc.$6.59-0.55 (-7.63%)Prev Close$7.14·MCap$362.4M·P/E—·Vol963.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
16
$4.54M
◆
Net Activity
Net Seller
$4.54M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at REGENXBIO Inc. (RGNX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 16 insider sales totaling $4.54M. The most recent insider transaction was by PAKOLA STEVE (officer: Chief Medical Officer), who sold $168.7K worth of shares on May 13, 2026. REGENXBIO Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $362.4M.
RGNX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 15,309 | $11.02 | $168.7K | 232,617 |
| Mar 12, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 5,124 | $10.35 | $53.0K | 247,926 |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,700 | $11.16 | $52.5K | 0 |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,267 | $11.16 | $58.8K | 0 |
| Jan 27, 2026 | Mills Kenneth T. | Director | Sell | 221,753 | $13.41 | $2.97M | 0 |
| Jan 2, 2026 | Simpson Curran | Chief Executive Officer | Sell | 18,559 | $14.40 | $267.3K | 0 |
| Jan 2, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 9,793 | $14.40 | $141.0K | 0 |
| Jan 2, 2026 | Malzahn Craig | Chief Technology Officer | Sell | 1,238 | $14.40 | $17.8K | 0 |
| Jan 2, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 18,247 | $14.40 | $262.8K | 0 |
| Oct 9, 2025 | Simpson Curran | Chief Executive Officer | Sell | 20,811 | $12.62 | $262.6K | 0 |
| Sep 29, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,624 | $10.03 | $76.5K | 0 |
| Sep 10, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,734 | $10.02 | $77.5K | 0 |
| Sep 1, 2025 | Chan Mitchell | Chief Financial Officer | Sell | 4,901 | $8.93 | $43.8K | 0 |
| Sep 1, 2025 | Malzahn Craig | Chief Technology Officer | Sell | 234 | $8.93 | $2.1K | 0 |
| Aug 1, 2025 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,699 | $8.19 | $38.5K | 0 |
| Jul 1, 2025 | Simpson Curran | Chief Executive Officer | Sell | 4,701 | $8.23 | $38.7K | 0 |
| May 12, 2025 | Mills Kenneth T. | Director | Sell | 20,602 | $7.91 | $163.0K | 0 |
| Feb 1, 2025 | Christmas Patrick J. | Chief Legal Officer | Sell | 4,700 | $8.07 | $37.9K | 0 |
| Feb 1, 2025 | Danos Olivier | Chief Scientific Officer | Sell | 5,452 | $8.07 | $44.0K | 0 |
| Feb 1, 2025 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,263 | $8.07 | $42.5K | 0 |
| Oct 2, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $10.11 | $101.1K | 11,286-47% | |
| Sep 4, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.56 | $115.6K | 11,986-45% | |
| Aug 5, 2024 | KARABELAS ARGERIS N | Sell | 10,100 | $13.51 | $136.5K | 11,786-46% | |
| Aug 5, 2024 | Simpson Curran | Chief Executive Officer | Sell | 100 | $15.00 | $1.5K | 170,037 |
| Jul 30, 2024 | KARABELAS ARGERIS N | Sell | 11,000 | $15.05 | $165.5K | 11,286-49% | |
| Jul 30, 2024 | Simpson Curran | Chief Executive Officer | Sell | 9,648 | $15.04 | $145.1K | 170,137 |
| Jul 26, 2024 | Mills Kenneth T. | Sell | 27,590 | $13.88 | $382.9K | 408,035 | |
| Jul 18, 2024 | Mills Kenneth T. | Sell | 2,410 | $13.77 | $33.2K | 408,035 | |
| Jul 3, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.27 | $112.7K | 11,286-47% | |
| May 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $15.81 | $237.2K | 408,035 |
| Apr 17, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $18.19 | $272.9K | 408,035 |
| Mar 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $21.86 | $327.9K | 408,035 |
| Mar 7, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 12,878 | $28.36 | $365.2K | 107,192 |
| Feb 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $16.76 | $251.3K | 418,383 |
| Jan 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $15.18 | $683.0K | 408,035 |
| Jan 4, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 17,237 | $17.39 | $299.8K | 107,192 |
| Dec 21, 2023 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $19.69 | $885.8K | 355,289 |
| Jan 5, 2023 | PAKOLA STEVE | Chief Medical Officer | Sell | 3,138 | $22.17 | $69.6K | 12,175 |
| Aug 31, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $30.24 | $72.6K | 135,160 |
| Aug 8, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 17,680 | $35.18 | $622.0K | 154,840 |
| Aug 3, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $31.26 | $75.0K | 155,240 |
| Jul 15, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 4,800 | $30.01 | $144.0K | 158,108 |
| Jan 4, 2022 | PAKOLA STEVE | Chief Medical Officer | Sell | 1,598 | $33.75 | $53.9K | 8,250 |
| Dec 27, 2021 | Fox Allan M. | Sell | 112,869 | $34.69 | $3.92M | 1,581,212 | |
| Nov 10, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $40.00 | $60.0K | 280,984 |
| Sep 29, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $42.19 | $63.3K | 280,984 |
| Sep 21, 2021 | Fox Allan M. | Director | Sell | 48,233 | $45.04 | $2.17M | 1,364,309 |
| Sep 15, 2021 | Mills Kenneth T. | President and CEO | Sell | 38,000 | $44.71 | $1.70M | 280,984 |
| Jun 28, 2021 | Mills Kenneth T. | President and CEO | Sell | 6,000 | $40.08 | $240.5K | 280,984 |
RGNX Insider Buying Activity
The following table shows recent insider purchases of REGENXBIO Inc. (RGNX) stock reported via SEC Form 4 filings.
No insider buying activity found for RGNX in the last 12 months.
RGNX Insider Selling Activity
The following table shows recent insider sales of REGENXBIO Inc. (RGNX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 15,309 | $11.02 | $168.7K | 232,617 |
| Mar 12, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 5,124 | $10.35 | $53.0K | 247,926 |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,700 | $11.16 | $52.5K | 0 |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,267 | $11.16 | $58.8K | 0 |
| Jan 27, 2026 | Mills Kenneth T. | Director | Sell | 221,753 | $13.41 | $2.97M | 0 |
| Jan 2, 2026 | Simpson Curran | Chief Executive Officer | Sell | 18,559 | $14.40 | $267.3K | 0 |
| Jan 2, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 9,793 | $14.40 | $141.0K | 0 |
| Jan 2, 2026 | Malzahn Craig | Chief Technology Officer | Sell | 1,238 | $14.40 | $17.8K | 0 |
| Jan 2, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 18,247 | $14.40 | $262.8K | 0 |
| Oct 9, 2025 | Simpson Curran | Chief Executive Officer | Sell | 20,811 | $12.62 | $262.6K | 0 |
| Sep 29, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,624 | $10.03 | $76.5K | 0 |
| Sep 10, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,734 | $10.02 | $77.5K | 0 |
| Sep 1, 2025 | Chan Mitchell | Chief Financial Officer | Sell | 4,901 | $8.93 | $43.8K | 0 |
| Sep 1, 2025 | Malzahn Craig | Chief Technology Officer | Sell | 234 | $8.93 | $2.1K | 0 |
| Aug 1, 2025 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,699 | $8.19 | $38.5K | 0 |
| Jul 1, 2025 | Simpson Curran | Chief Executive Officer | Sell | 4,701 | $8.23 | $38.7K | 0 |
| May 12, 2025 | Mills Kenneth T. | Director | Sell | 20,602 | $7.91 | $163.0K | 0 |
| Feb 1, 2025 | Christmas Patrick J. | Chief Legal Officer | Sell | 4,700 | $8.07 | $37.9K | 0 |
| Feb 1, 2025 | Danos Olivier | Chief Scientific Officer | Sell | 5,452 | $8.07 | $44.0K | 0 |
| Feb 1, 2025 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,263 | $8.07 | $42.5K | 0 |
| Oct 2, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $10.11 | $101.1K | 11,286-47% | |
| Sep 4, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.56 | $115.6K | 11,986-45% | |
| Aug 5, 2024 | KARABELAS ARGERIS N | Sell | 10,100 | $13.51 | $136.5K | 11,786-46% | |
| Aug 5, 2024 | Simpson Curran | Chief Executive Officer | Sell | 100 | $15.00 | $1.5K | 170,037 |
| Jul 30, 2024 | KARABELAS ARGERIS N | Sell | 11,000 | $15.05 | $165.5K | 11,286-49% | |
| Jul 30, 2024 | Simpson Curran | Chief Executive Officer | Sell | 9,648 | $15.04 | $145.1K | 170,137 |
| Jul 26, 2024 | Mills Kenneth T. | Sell | 27,590 | $13.88 | $382.9K | 408,035 | |
| Jul 18, 2024 | Mills Kenneth T. | Sell | 2,410 | $13.77 | $33.2K | 408,035 | |
| Jul 3, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.27 | $112.7K | 11,286-47% | |
| May 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $15.81 | $237.2K | 408,035 |
| Apr 17, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $18.19 | $272.9K | 408,035 |
| Mar 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $21.86 | $327.9K | 408,035 |
| Mar 7, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 12,878 | $28.36 | $365.2K | 107,192 |
| Feb 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $16.76 | $251.3K | 418,383 |
| Jan 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $15.18 | $683.0K | 408,035 |
| Jan 4, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 17,237 | $17.39 | $299.8K | 107,192 |
| Dec 21, 2023 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $19.69 | $885.8K | 355,289 |
| Jan 5, 2023 | PAKOLA STEVE | Chief Medical Officer | Sell | 3,138 | $22.17 | $69.6K | 12,175 |
| Aug 31, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $30.24 | $72.6K | 135,160 |
| Aug 8, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 17,680 | $35.18 | $622.0K | 154,840 |
| Aug 3, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $31.26 | $75.0K | 155,240 |
| Jul 15, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 4,800 | $30.01 | $144.0K | 158,108 |
| Jan 4, 2022 | PAKOLA STEVE | Chief Medical Officer | Sell | 1,598 | $33.75 | $53.9K | 8,250 |
| Dec 27, 2021 | Fox Allan M. | Sell | 112,869 | $34.69 | $3.92M | 1,581,212 | |
| Nov 10, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $40.00 | $60.0K | 280,984 |
| Sep 29, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $42.19 | $63.3K | 280,984 |
| Sep 21, 2021 | Fox Allan M. | Director | Sell | 48,233 | $45.04 | $2.17M | 1,364,309 |
| Sep 15, 2021 | Mills Kenneth T. | President and CEO | Sell | 38,000 | $44.71 | $1.70M | 280,984 |
| Jun 28, 2021 | Mills Kenneth T. | President and CEO | Sell | 6,000 | $40.08 | $240.5K | 280,984 |
RGNX Insiders
Similar Stocks to RGNX
VRTX
Vertex Pharmaceuticals Incorporated
$427.38-2.51%
$113.59B
REGN
Regeneron Pharmaceuticals, Inc.
$603.95+0.53%
$63.34B
ALNY
Alnylam Pharmaceuticals, Inc.
$287.55-2.80%
$40.32B
RVMD
Revolution Medicines, Inc.
$152.43-6.87%
$33.48B
UTHR
United Therapeutics Corporation
$540.37-0.78%
$23.64B
INSM
Insmed Incorporated
$103.86-2.06%
$23.17B
INCY
Incyte Corporation
$93.45-2.23%
$19.33B
MRNA
Moderna, Inc.
$45.94-0.23%
$18.72B